NASDAQ:HRTX Heron Therapeutics Q2 2026 Earnings Report $0.52 +0.02 (+4.59%) As of 12:28 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Heron Therapeutics EPS ResultsActual EPSN/AConsensus EPS -$0.02Beat/MissN/AOne Year Ago EPSN/AHeron Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$42.19 millionBeat/MissN/AYoY Revenue GrowthN/AHeron Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeBefore Market OpensConference Call DateMonday, August 10, 2026Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Heron Therapeutics Earnings HeadlinesHeron Therapeutics to Report Second Quarter 2026 Financial Results on August 10 July 27, 2026 | quiverquant.comQHeron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026July 27, 2026 | globenewswire.comBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership with Nvidia - one he believes positions it ahead of Tesla in the autonomous vehicle race. With a market-moving announcement expected on July 31st, Chaikin is urging investors to swap overpriced AI stocks for this under-the-radar name before markets open. He's also releasing a free Hotlist and Hitlist of buy and sell ideas for the second half of 2026.August 3 at 1:00 AM | Chaikin Analytics (Ad)Is Heron Therapeutics, Inc. (HRTX) Stock a Recovery Opportunity After Cinvanti Patent Court Ruling?June 30, 2026 | finance.yahoo.comHeron Therapeutics (HRTX) Stock Sees Fair Value Cut After Cinvanti Patent DecisionJune 28, 2026 | finance.yahoo.comHeron Therapeutics (HRTX) Receives a Buy from H.C. WainwrightJune 9, 2026 | theglobeandmail.comSee More Heron Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Heron Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heron Therapeutics and other key companies, straight to your email. Email Address About Heron TherapeuticsHeron Therapeutics (NASDAQ:HRTX) is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids. Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S. Food and Drug Administration approval in 2016 for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. The company also advanced HTX-019, an injectable emulsion formulation of aprepitant, which obtained FDA approval as the first non-polyethylene glycol formulation for acute CINV prophylaxis in adults. The company’s most advanced pipeline candidate is HTX-011, an investigational, long-acting, non-opioid local anesthetic that combines bupivacaine and low-dose meloxicam. HTX-011 is designed to provide extended post-operative analgesia and has been evaluated in Phase III trials across multiple surgical settings. In addition to HTX-011, Heron is developing other drug candidates to address various analgesic and supportive care needs and is exploring strategic collaborations to broaden the commercial reach of its portfolio. Founded in 2011 and headquartered in Redwood City, California, Heron Therapeutics completed its initial public offering in 2015 and is listed on Nasdaq under the ticker HRTX. The company primarily serves the U.S. market and is pursuing global partnerships to expand its geographic footprint. Heron’s leadership team comprises industry veterans with expertise in clinical development, regulatory affairs and commercialization, supporting the company’s mission to deliver innovative treatments that enhance patient care.View Heron Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Strategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31A Sweet Beat and a Wearables Rally Came With Reasons to PauseChevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong SignalAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case Upcoming Earnings Spotify Technology (8/4/2026)SpaceX (8/4/2026)Electronic Arts (8/4/2026)McDonald's (8/4/2026)Toyota Motor (8/4/2026)BP (8/4/2026)EOG Resources (8/4/2026)Energy Transfer (8/4/2026)Marathon Petroleum (8/4/2026)Mplx (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
